Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study

por Ishihara, Hisamitsu, Yamaguchi, Susumu, Nakao, Ikko, Sakatani, Taishi
Publicado 2018

Efficacy and safety of ipragliflozin as add‐on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi‐centre, randomized, placebo‐controlled, doubl...

por Ishihara, Hisamitsu, Yamaguchi, Susumu, Nakao, Ikko, Okitsu, Akira, Asahina, Seitaro
Publicado 2016